This expansion marks another milestone in Siegfried's efforts to further strengthen its biologics offering, particularly in the rapidly growing cell and gene therapy market.

The state-of-the-art laboratory includes world-class pilot facilities that will enable Dinamiqs to offer viral vector design, analysis, and manufacturing services to meet the growing needs of the cell and gene therapy market. The laboratory is an integral part of Dinamiqs' 2,500m² cGMP manufacturing facility, which is currently under construction and will be operational by the end of 2025. This facility will have a production capacity of up to 1,000 liters for the manufacture of viral vectors for research and development, clinical trials, and commercial purposes.

“Aligned with Siegfried's strategy Evolve⁺, the new lab facility marks a key milestone in Dinamiqs' journey to becoming the leading CDMO in the cell and gene therapy space," commented Marcel Imwinkelried, Chief Executive Officer Siegfried. "The team is making significant strides toward bringing Dinamiqs' capabilities to commercial scale."

"We know about the importance of leading process development and analytics for the success of viral vector projects," added Martin Kessler, Chief Executive Officer Dinamiqs. "This is why we have expanded our Swiss labs significantly. From the optimization of genomes to GMP scale-up, our clients now get everything out of one hand."